Biotech Stocks and ETFs Can Get Their Grooves Back

As is now widely documented, biotechnology stocks and exchange traded funds endured a rough 2021. Compounding those woes is the fact that investors were caught off guard by last year’s lethargy because biotechnology assets surged in 2020. As a result, it’s not surprising that...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.